BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Prior to recent therapeutic innovations in the bladder space, what challenges or unmet needs did you face when treating ...

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

Intravesical BCG therapy: Widely used for treating bladder cancer. BCG vaccine for TB prevention: Traditionally administered to infants and children. In recent years, there has been a growing ...

Options for BCG-unresponsive NMIBC have expanded dramatically in the last few years. While it used to be that options were limited to regular intravesical chemotherapy or surgery, that changed ...

Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data on nadofaragene ...

Multicenter Analysis of Oncological Outcomes and Risk Dynamics EAU 2024: Subsequent Therapies After Intravesical BCG in Patients with Bladder Cancer: Analysis of Real-World Treatment Patterns EAU 2024 ...

TAR-200, an intravesical drug system, previously received FDA breakthrough therapy designation in December 2023. A new drug application has been initiated with the FDA for TAR-200 to treat ...

Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has survived to this date. BCG is superior to chemotherapy as an adjuvant agent ...

The filing seeks approval for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or ...